The capsular serotype of Streptococcus pneumoniae is more important than the genetic background for resistance to complement.
The polysaccharide capsule of Streptococcus pneumoniae inhibits phagocytic killing by innate immune mechanisms. Certain serotypes are associated with invasive disease while others with a nasopharyngeal carriage. The invasiveness of serotypes may partly be explained by ability to resist deposition of complement (C3) on the bacterial surface and consequent opsonophagocytic killing. In our previous studies, we observed that clinical isolates of serotypes 1 and 5, which are rarely detected in asymptomatic carriage, were resistant to complement deposition and opsonophagocytosis, whereas serotypes 6B and 23F, both common in carriage, were more sensitive to deposition of C3 and opsonophagocytic killing. However, presence of significant variation in C3 deposition between isolates of the same serotype indicated that factors other than the capsule also affect complement resistance. To distinguish the relative effect of the capsular serotype and other virulence factors on C3 deposition, we compared capsule-switched mutants prepared in genetic backgrounds of pneumococcal strains TIGR4, 603, and 618. Clinical isolates which had the same multilocus sequence type but expressed different serotypes were also compared. We found that the serotype had a significant impact on complement resistance and that the more resistant the strain was to complement, the higher was the concentration of polysaccharide-specific antibodies required for opsonophagocytic killing. Comparison of strains expressing the same capsular polysaccharides in the different genetic backgrounds and various capsular mutants of the same strain suggests that while the genotype affects complement resistance, the serotype is the most important determinant. Differences between serotypes were more significant than the differences between strains.
Melin
Merit
M
National Institute for Health and Welfare, Department of Vaccination and Immune Protection, Helsinki, Finland. merit.melin@thl.fi
Trzciński
Krzysztof
K
Meri
Seppo
S
Käyhty
Helena
H
Väkeväinen
Merja
M
D000328:Adult; D000907:Antibodies, Bacterial / Q000276:immunology; D016667:Bacterial Capsules / Q000235:genetics / Q000276:immunology*; D003167:Complement Activation / Q000276:immunology*; D003176:Complement C3 / Q000276:immunology; D005434:Flow Cytometry; D006801:Humans; D010587:Phagocytosis / Q000276:immunology; D011008:Pneumococcal Infections / Q000276:immunology* / Q000382:microbiology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity; D037521:Virulence Factors / Q000235:genetics / Q000276:immunology
D000907:Antibodies, Bacterial; D003176:Complement C3; D011135:Polysaccharides, Bacterial; D037521:Virulence Factors